GlassScriptPhysician profile
Saiyun Hou
NPI 1326464660
$3,909.59
in general payments reported to CMS, 2019-2025
35 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $421 · 2021: $649 · 2022: $939 · 2023: $717 · 2024: $599 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $721.56 | 2020-2025 | Belbuca |
| Nevro Corp. | $530.35 | 2019-2024 | Senza |
| Lilly USA, LLC | $236.46 | 2020-2023 | Reyvow, Emgality |
| Electronic Waveform Lab, INC. | $225.24 | 2022 | |
| Scilex Pharmaceuticals INC. | $217.28 | 2020-2023 | Ztlido |
| Boston Scientific Corporation | $210.68 | 2019-2025 | Wavewriter Alpha Prime 16, Infinion 16 |
| Biohaven Pharmaceuticals, INC. | $188.92 | 2021 | |
| Biotissue Holdings INC. | $139.04 | 2023 | |
| Abbott Laboratories | $129.17 | 2021-2023 | Octrode |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.09 | 2019-2024 | Relistor |
| Arbor Pharmaceuticals, INC. | $107.90 | 2021-2022 | |
| Pfizer INC. | $91.91 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.85 | 2022 | |
| Spr Therapeutics, INC | $88.00 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86.74 | 2022 | |
| Impel Pharmaceuticals INC. | $77.76 | 2023 | Trudhesa |
| Medtronic, INC. | $59.24 | 2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Accurian |
| Curonix LLC | $54.71 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ibsa Pharma INC. | $42.11 | 2020-2022 | |
| Abbvie INC. | $37.61 | 2023 | |
| Nalu Medical, INC. | $34.06 | 2024 | Nalu Neurostimulation System |
| Stimwave Technologies Incorporated | $33.74 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $33.30 | 2025 | |
| Redhill Biopharma INC. | $32.79 | 2020-2021 | |
| Painteq LLC | $32.51 | 2021-2023 | Painteq |
| Eisai INC. | $30.59 | 2021 | |
| Impel Pharmaceuticals LLC | $21.29 | 2024 | Trudhesa |
| Zimmer Biomet Holdings, INC. | $21.21 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Globus Medical, INC. | $20.32 | 2025 | Senza |
| Lundbeck LLC | $17.77 | 2022 | |
| Spinal Simplicity, LLC | $14.84 | 2023 | Ha Minuteman G3-R |
| Almatica Pharma LLC | $13.25 | 2021 | |
| Indivior INC. | $12.88 | 2021 | |
| Pacira Therapeutics, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saiyun Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.